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3 Controversy persists over the benefits of low- versus standard-dose intravenous alteplase for 
4 treatment of acute ischaemic stroke (AIS).  We sought to determine individual patient factors that 
5 contribute to the risk-benefit balance of low-dose alteplase treatment..
6 Methods
7 Observational study using data from the Enhanced Control of Hypertension and Thrombolysis 
8 Stroke Study (ENCHANTED), an international, randomised, open-label, blinded-endpoint trial 
9 that assessed low-dose (0·6mg/kg) versus standard-dose (0·9mg/kg) intravenous alteplase in AIS 
10 patients.  Logistic regression models were used to estimate the benefit of good functional outcome 
11 (scores 0 or 1 on the modified Rankin scale [mRS] at 90-days) and risk (symptomatic intracerebral 
12 haemorrhage [sICH]), under both regimens for individual patients.  The net advantage for low-
13 dose, relative to standard-dose, alteplase was calculated by dividing excess benefit by excess risk 
14 according to a combination of patient characteristics.  The algorithms were externally validated in 
15 a nationwide acute stroke registry database in South Korea.
16 Results
17 Patients with an estimated net advantage from low-dose alteplase, compared with without, were 
18 younger (mean age of 66 vs. 75 years), had lower systolic blood pressure (BP) (148 vs. 160 mmHg), 
19 lower National Institute of Health Stroke Scale score (median of 8 vs. 16), and no atrial fibrillation 
20 (AF) (10.3% vs. 97.4%), diabetes mellitus (DM) (19.2% vs. 22.4%) or pre-morbid symptoms 
21 (defined by mRS=1) (16.3% vs. 37.8%).
22 Conclusion
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1 Use of low-dose alteplase may be preferable in AIS patients with a combination of favourable 
2 characteristics, including younger age, lower systolic BP, mild neurological impairment, and no 
3 AF, DM, or pre-morbid symptoms.
4




2 Alteplase is the only established thrombolytic treatment for acute ischaemic stroke (AIS), with 
3 most guidelines recommending an intravenous dose of 0·9 mg/kg for eligible AIS patients.(1, 2)  
4 However, the are data to suggest that Asians are at increased risk for symptomatic intracerebral 
5 haemorrhage (sICH); this led to a lower dose of 0·6 mg/kg of alteplase being approved in Japan,(3, 
6 4) which has been variably adopted by clinicians elsewhere in Asia and beyond.
7 In the Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED),5-7 
8 low-dose alteplase was not f und to be statistically non-inferior to a standard-dose alteplase on the 
9 conventional binary outcome of death or any disability, defined by scores 2 to 6 on the modified 
10 Rankin scale (mRS) at 90 days after the onset of symptoms.7  However, low-dose alteplase was 
11 found to be non-inferior for overall functional recovery, through ordinal analysis of the mRS, and 
12 to clearly reduce the risk of sICH, the most worrisome complication of this treatment.(5-7)
13 A combination of patient characteristics may influence the risk-benefit balance of low-dose 
14 relative to standard-dose alteplase in AIS patients.(8-10)  The aim of this study was to develop 
15 clinical prediction models that incorporate plausible risk and benefit estimates in order to 
16 determine individual patient factors that contribute to the risk-benefit balance of low-dose 
17 compared with standard-dose alteplase treatment.
18 METHODS
19 Development cohort
20 The ongoing ENCHANTED trial is an international, multi-centre, quasi-factorial, prospective, 
21 randomised, open-label, blinded-endpoint trial; the details of which are outlined elsewhere.(5-7)  
22 The alteplase-dose arm of the trial has concluded, where 3310 patients with a clinical diagnosis of 
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1 AIS confirmed on brain imaging and fulfilling standard criteria for thrombolysis treatment, 
2 including symptom onset within 4.5 hours, were randomly assigned to receive low- (0.6mg/kg; 15% 
3 as bolus, 85% as infusion over 1 hour) or standard-dose (0.9mg/kg; 10% as bolus, 90% as infusion 
4 over 1 hour) alteplase.  The intensity of blood pressure (BP) control arm of the trial is ongoing and 
5 due to report results in 2019.  The study protocol was approved by the appropriate ethics committee 
6 at each participating centre, and written informed consent was obtained from each patient or an 
7 appropriate surrogate.
8 Key demographic and clinical characteristics were recorded at the time of enrolment of patients, 
9 with the severity of neurological impairment measured using the National Institutes of Health 
10 Stroke Scale (NIHSS) at baseline, 24 hours, and at Day 7 (or on discharge from hospital where 
11 this was earlier).  Digital images of all baseline and follow-up CT, MRI and angiogram images, 
12 were uploaded for central review by independent assessors blind to clinical data, treatment, and 
13 date and sequence of scan using MIStar version 3·2 (Apollo Medical Imaging Technology, 
14 Melbourne, Victoria, Australia).  Assessors graded any haemorrhage as intracerebral, 
15 subarachnoid, intraventricular, subdural or other; sICH was graded across all standard 
16 definitions.(7)
17 Validation cohort
18 Study subjects were selected from a prospective, multi-centre, nationwide acute stroke registry 
19 database in South Korea, which was established in April 2008 and described in detail 
20 elsewhere.(11, 12)  The collaborative registry study group consisted of 15 academic and regional 
21 stroke centres as of July 2014.  Participating centres enrolled consecutive acute stroke cases 
22 admitted within 7 days from onset into a web-based database system.  Study data were regularly 
23 audited by the central adjudication committee using pre-specified query sequences.  Acute stroke 
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1 management, including use of recanalization therapy, was performed according to current clinical 
2 guidelines and institutional protocols, at the discretion of individual physicians who managed the 
3 patients.(13)  Information on patient characteristics and treatments were obtained from the registry 
4 database.
5 Outcomes
6 A beneficial outcome was defined as excellent functional recovery according to scores 0 or 1 on 
7 the mRS at 90 days: this was the primary efficacy outcome in the alteplase-dose arm of the 
8 ENCHANTED trial.  A risk outcome was defined as sICH according to the Safe Implementation 
9 of Thrombolysis in Stroke-Monitoring Study (SITS-MOST).
10 Statistical analysis
11 Two logistic regression models were developed: one for the prediction of benefit and the other for 
12 the prediction of risk.  Significant predictors (P<0.1) from the univariate analyses and randomised 
13 dose arm were tested for their associations with outcomes in multivariable models.  The full models 
14 were reduced by successively removing the non-significant covariates until all the remaining 
15 predictors remained statistically significant (P<0.05).  Randomised treatment group was forced 
16 into the models.  Collinearity and interaction between variables were checked.  Significant two-
17 way and three-way interactions (P <0·05) between variables were included in models.  The models 
18 were validated in the South Korean acute stroke registry database.  Performance of the final 
19 prediction models was assessed using an area under the receiver-operating-characteristic curve 
20 (AUROC), with c-statistic for discriminative ability and the Hosmer–Lemeshow goodness-of-fit 
21 statistic for calibration.(14)
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1 The models were constructed to estimate the probabilities of benefit and risk for any patient 
2 according to low- and standard-dose alteplase.  The treatment variable was fixed in turn to low-
3 dose and standard-dose alteplase, with the probabilities of benefit and risk for subject i represented 
4 as  and , and  and , respectively, for the two doses.  The net advantage of low-dose 𝐵𝐿𝑖 𝐵𝑆𝑖 𝑅𝐿𝑖 𝑅𝑆𝑖
5 alteplase is defined as  / .  A net advantage >1 therefore indicates the (𝐵𝐿𝑖 ― 𝐵𝑆𝑖 ) (𝑅𝐿𝑖 ― 𝑅𝑆𝑖 )
6 superiority of low-dose alteplase.   However, this methodology assumes that benefit and risk have 
7 equal weight, which may not be acceptable to some clinicians.  Thus, a weighted net advantage 
8 was assigned as  / , where w is the relative weight (between 0 and 𝑤(𝐵𝐿𝑖 ― 𝐵𝑆𝑖 ) (1 ― 𝑤)(𝑅𝐿𝑖 ― 𝑅𝑆𝑖 )
9 1) given to benefit.  For example, if the risk of harm from sICH is considered to be more important, 
10 and the clinician should wish to disregard potential functional benefits from treatment, w should 
11 be set close to 0.  Conversely, if the risk of harm from sICH is considered to be less important, and 
12 wishes to focus on positive functional outcome, then w should be set close to 1.  The equations to 
13 estimate the probabilities were shown in SFigure I.  Two-sided P values were reported and P <0·05 
14 was considered statistically significant.  SAS version 9·3 (SAS Institute, Cary, NC) was used in 
15 all analyses.(5)
16 Results
17 Model development and performance
18 All patients with complete information (n=3197) were included in the benefit analysis: 1530 
19 patients (47·8%) had an excellent outcome; 48·9% and 46.8% had an excellent outcome in the 
20 low-dose and standard-dose alteplase groups, respectively.  The characteristics of included patients 
21 by mRS scores 0-1 versus 2-6 are shown in STable 1.  Patients with an excellent functional 
22 outcome were significantly more likely to be young, male, of Asian ethnicity, with a mild 
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1 neurological deficit, with fewer co-morbidities (including previous stroke, coronary artery disease, 
2 diabetes mellitus [DM], and atrial fibrillation [AF]), and lower prior use of warfarin, aspirin, and 
3 statin therapy, at baseline.  After successively removing non-significant covariates from the 
4 multivariable model, only age, systolic BP, baseline NIHSS score, pre-morbid level of function 
5 [estimated mRS score], and history of AF and DM remained significant.  Randomized treatment 
6 group was forced into the model to estimate the predicted probabilities according to alteplase dose.  
7 A significant interaction between age and AF was identified and included in the model (Table 1).  
8 No collinearity was found.  The final model shows good discriminative ability (c-statistic 0·75, 
9 SFigure II) and excellent calibration (Hosmer–Lemeshow P=0.54, SFigure III).
10 In order to produce estimates for the same population, only patients included in the benefit analysis 
11 were included in the risk analysis: 51 (1·6 %) had sICH, including 1% and 2·2% in the low-dose 
12 and standard-dose alteplase groups, respectively.  Patients with sICH were significantly more 
13 likely to be older, with a severe neurological deficit, and with history of co-morbidities (including 
14 hypertension, previous stroke, coronary artery disease, DM, and AF) and prior use of aspirin at 
15 baseline (Stable 2).  The final model includes systolic BP, AF and randomised dose arm (Table 2), 
16 and demonstrates good discrimination (c-statistic 0·71, SFigure II) and excellent calibration 
17 (Hosmer–Lemeshow P=0.44, SFigure III).  No collinearity or interactions were found.
18 Model validation and performance
19 There were 1526 (29.5% were treated by low-dose alteplase) patients included in the analysis from 
20 the acute stroke registry dataset.  The benefit model demonstrated both good discrimination(C-
21 statistic: 0.76) and calibration (Hosmer–Lemeshow P=0.30).  The risk model demonstrated 
22 moderate discrimination (0.62) and good calibration (P=0.83) Both the benefit and risk model 
23 demonstrated good discrimination (C-statistic: 0.76 and 0.62, respectively;( SFigure IV). and 
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1 calibration (Hosmer–Lemeshow P=0.30 and P=0.83, respectively).    Predicted and observed 
2 probabilities of the outcomes in the validation data set corresponded well to over one tenth of 
3 predicted probability (Figure 1).
4 Net advantage from low-dose alteplase according to patient characteristics
5 AIS patients had a net advantage from low-dose alteplase when they were younger, had lower 
6 systolic BP, mild neurological deficit, and no AF, DM or pre-morbid symptoms (mRS=1) (Table 
7 3).  In the validation cohort, those with a net advantage had the same combination of characteristics 
8 to the development cohort (Table 3).  When benefit and risk were assigned different weight, results 
9 followed a similar pattern (STable 3).
10 Discussion
11 The present analysis from ENCHANTED, the only large-scale randomised evaluation of different 
12 doses of intravenous alteplase for the treatment of AIS, demonstrates that patient-specific 
13 characteristics may determine the anticipated individual effects of low-dose alteplase in terms of 
14 benefits of an excellent outcome (mRS 0-1 at 90 days) and increased risk of sICH.  The model 
15 demonstrated good discriminative ability and was well calibrated when externally validated in the 
16 nationwide acute stroke registry dataset from South Korea.  Low-dose alteplase appears optimal 
17 in younger patients who have lower systolic BP, mild neurological deficit, and an absence of major 
18 cardiovascular co-morbidities or pre-morbid symptoms.
19 A risk-benefit algorithm was generated from the ENCHANTED trial, where the percentage of 
20 excellent outcome (mRS 0-1) was 48·9% and 46.8% in the randomised low-dose and standard-
21 dose alteplase groups, respectively, but where low-dose alteplase reduced the risk of sICH 
22 significantly by 52% according to the SITS-MOST definition.  However, this information pertains 
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1 to group level and it is not informative over the choice of dose of alteplase at an individual patient 
2 level.  Furthermore, important secondary analyses failed to identify any patient subgroup that can 
3 clearly benefit from low-dose alteplase.  Our approach, therefore, was to develop a risk score that 
4 incorporated multiple patient-specific variables, in order to determine the balance of benefit and 
5 risk for an individual patient according to a combination of characteristics.
6 Our analyses confirm that age, systolic BP, neurological severity, co-morbid AF and DM, and pre-
7 morbid symptoms, are important factors that influence outcome in thrombolysis-treated AIS 
8 patients;(15-17) these factors also form components of established risk scores.(18),(19)  More 
9 specifically, we have shown a net advantage from low-dose alteplase for younger patients with a 
10 normal level of systolic BP (i.e. <140mmHg), mild neurological deficit (i.e. score <10 on NIHSS), 
11 and no AF, DM or pre-morbid symptoms; factors which are known to predict good functional 
12 outcome and lower risk of sICH after AIS.(17, 20, 21)  It is possible that mild AIS patients with a 
13 favourable risk profile and inherently favourable prognosis simply benefit from a reduced risk of 
14 sICH when they are treated with low-dose alteplase.  However, they may also be less likely to have 
15 greater ischaemic deficit from large vessel occlusions that are more resistant to low- compared 
16 with standard-dose alteplase, thus avoiding the potential reduced lytic efficacy associated with 
17 under treatment.
18 Following on, there are plausible reasons that low-dose alteplase was less effective in severe AIS 
19 patients with an unfavourable risk profile, in this case those who were older, had higher systolic 
20 BP, severe neurological impairment, co-morbid AF and DM, and pre-morbid symptoms.  This may 
21 again reflect stroke aetiology; those with higher risk profiles are more likely to have large vessel 
22 occlusion and/or greater thrombus length where low-dose alteplase is potentially less effective in 
23 achieving recanalization.(8, 22)  They may therefore be subject to excess harm from the sequelae 
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1 of failed recanalization such as infarct extension, cerebral oedema and need for decompressive 
2 hemicraniectomy, despite lower rates of sICH.  We did not have access to neuroimaging data on 
3 these factors in the present analyses, and future analysis of the brain images acquired from 
4 participants in ENCHANTED (5000+ scans) may confirm or refute this hypothesis.
5 In regard to BP, observational data from the SITS registry (23, 24) revealed that high systolic BP 
6 post-thrombolysis is associated with sICH and poor outcome.(23)  In particular, the most 
7 favourable outcome was in those with systolic BP levels of 141-150 mmHg between 2–24 hours 
8 after thrombolysis.(24)  Systolic BP was an important factor in our risk-benefit model, but not in 
9 a way that one might initially anticipate; patients at higher risk of sICH due to elevated BP did not 
10 benefit from low-dose alteplase.  Instead, the present model suggests patients with favourable 
11 characteristics that include lower systolic BP had greater net advantage from low-dose alteplase.  
12 This is due to the characteristics being considered in combination rather than individually.  The 
13 ongoing ENCHANTED BP arm(6) will provide insight as to whether more intensive BP lowering 
14 (systolic target 130-140 mmHg) has superior efficacy and lower risk of ICH compared to 
15 longstanding guideline recommendations (systolic target <180 mmHg) in the context of 
16 thrombolysis in AIS.
17 Interpretation of the present model should be done in the context of the original trial, where, in the 
18 primary group-level analyses, low-dose alteplase was not shown to be non-inferior to standard-
19 dose, nor did it perform significantly well in a particular subgroup according to single patient 
20 characteristics.(7-10, 25)  The novel value of the current predictive model arises from the use of a 
21 combination of clinically significant and routinely available patient characteristics that constitute 
22 a profile for which low-dose alteplase confers a net advantage.  The potential utility of low-dose 
23 alteplace in this context has scientific plausibility through the mechanisms discussed above, and 
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1 furthermore, was externally validated using real-world registry data.  However, there was much 
2 less sICH in ENCHANTED according to SITS-MOST criteria compared with that in the stroke 
3 registry using a comparable but less specific criteria.  Therefore, the risk model performs less 
4 optimistically due to lower discriminative ability.  This is an unavoidable limitation of comparing 
5 clinical trial definitions with those applied to registries.  It is also worth noting that the majority of 
6 participants in ENCHANTED were Asian, and the model was validated in a Korean cohort, thus 
7 its applicability to other groups in unknown.
8 In conclusion, the beneficial effects of low-dose alteplase in the individual patient, in terms of 
9 improving the probability of excellent outcome (mRS 0-1) and reducing the risk of sICH, can be 
10 quantified using a multivariable risk algorithm.  Low-dose alteplase appears optimal in patients 
11 with mild AIS and a favourable risk profile.  Future studies should aim to determine the effects of 
12 low-dose vs. standard dose alteplase in subgroups according to neuroimaging characteristics, such 
13 as thrombus burden and infarct volume, as well as associations of low-dose alteplase with 
14 subsequent infarct extension, cerebral edema and hemicraniectomy.    These findings may also 
15 support future research that focuses on low-dose thrombolysis in mild AIS patients, for example 
16 in those who are not eligible for mechanical thrombectomy.
17
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2 Figure 1  Predicted vs. observed probabilities of outcomes in the validation model
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1 Table 1  Final predictive model for benefit* at 90 days
Estimate    SE P value
Age (years) -0.0117 0.00355 0.001
   Systolic BP (mmHg) -0.00598 0.00204 0.003
   NIHSS score
     0-4 Ref
     5-10 -0.9667 0.1102 <0.0001
     11-15 -1.9048 0.1299 <0.0001
     ≥16 -2.4569 0.1431 <0.0001
   Atrial fibrillation 1.3955 0.6471 0.031
   Diabetes mellitus -0.2604 0.0996 0.009
   No significant disability (mRS=1) -0.7921 0.1089 <0.0001
Randomised to low-dose alteplase treatment -0.1443 0.0788 0.067
Age*atrial fibrillation -0.0238 0.00905 0.009
2 BP: blood pressure; NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin scale; SE: 
3 standard error
4 * defined according to scores 0-1 on the mRS at 90-days
5
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1 Table 2: Final predictive model for the risk of symptomatic intracranial haemorrhage*
Estimate SE P value
   Systolic BP (mmHg) 0.0206 0.007
83
0.009
   Atrial fibrillation 1.3316 0.2 7
3
<0.000
1Randomised to low-dose alteplase treatment -0.8018 0.305
4
0.009
2 BP: blood pressure; SE: standard error
3 *defined according to the Safe Implementation of Thrombolysis in Stroke-Monitoring Study 
4 (SITS-MOST)
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1 Table 3 Patient characteristics by net advantage from low-dose alteplase
Development cohort Validation cohort
Net advantage from 
low-dose alteplase No (n=339, 11%) Yes (n=2858, 89%) No (n=363, 24%) Yes (n=1162, 76%)
Age, years 75(10.4) 66(12.7) 74(10.3) 66(12.5)
Systolic BP, mmHg 160(14.8) 148(19.9) 164(26.3) 143(26.1)
NIHSS 16(10-20) 8(5-13) 16(12-20) 9(5-14)
Pre-stroke mRS=0 211(62.2%) 2393(83.7%) 236(65.0%) 1044(89.9%)
Atrial fibrillation 330(97.4%) 294(10.3%) 322(88.7%) 302(26.0%)
Diabetes mellitus 76(22.4%) 549(19.2%) 104(28.7%) 267(22.9%)
2 BP: blood pressure; mRS: modified Rankin scale; NIHSS: National Institute of Health Stroke Scale
3
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